← All articles
Longevity

Lipoprotein(a): The Hidden Heart Attack Predictor Found in One in Five People

About 20% of people have genetically elevated Lp(a) — a marker not included in a standard blood panel. At levels above 120 mg/dL, heart attack risk increases 3–4 times regardless of "good" and "bad" cholesterol. Leading cardiology associations recommend testing it at least once in a lifetime.

6 min readLongevity04.09.2026
Quick Answer

Lp(a) is elevated (≥50 mg/dL) in about 20% of people worldwide; 70–90% of the level is genetically determined and does not change with diet or exercise. At levels above 120 mg/dL, heart attack risk increases 3–4 times. A standard blood test does not include this marker — it must be ordered separately.

What is Lp(a) and how does it differ from regular LDL?

Lipoprotein(a), or Lp(a), is a particle structurally similar to low-density lipoprotein (LDL), but carrying an additional protein — apolipoprotein(a). This fundamentally changes its behavior: Lp(a) not only transports cholesterol, but also inhibits fibrinolysis — the process of dissolving blood clots. In addition, Lp(a) accumulates in the vessel wall and promotes inflammation, accelerating the formation of atherosclerotic plaques.

Lp(a) levels are measured in mg/dL or nmol/L. Due to differences in apolipoprotein(a) size between individuals, both units are used in clinical practice. The European Atherosclerosis Society (EAS, 2022) recommends nmol/L as the more accurate unit; the high-risk threshold is ≥125 nmol/L, approximately equivalent to ≥50 mg/dL.

How common is elevated Lp(a) and why does it matter?

According to a 2024 systematic review (Patel et al., Frontiers in Cardiovascular Medicine), Lp(a) levels are 70–90% genetically determined. Lifestyle, diet, and physical activity have virtually no effect on this marker. This means a person can have elevated Lp(a) with normal LDL and HDL, normal weight, and no other risk factors.

Approximately 20% of the world's population (about 1.5 billion people) have Lp(a) ≥50 mg/dL. Among Black Americans, the prevalence of elevated Lp(a) is higher than in White or Asian populations. Yet Lp(a) is not included in a standard "lipid panel" — it must be ordered separately, which many physicians do infrequently.

Lp(a) is the most common inherited lipid disorder and one of the strongest genetic predictors of cardiovascular disease.

How does Lp(a) increase the risk of heart attack, stroke, and aortic stenosis?

The link between Lp(a) and cardiovascular disease has been studied in large cohort and Mendelian randomization studies. Mendelian randomization — a method using genetic variants as a "natural experiment" — points to a causal role, not merely an association.

  • Myocardial infarction: at Lp(a) levels above 120 mg/dL, Mendelian randomization data show a 3–4 times increase in relative risk (Patel et al., Front. Cardiovasc. Med., 2024).
  • MACE overall: a meta-analysis of 14 studies (Dong et al., PMC11608083, 2024) in patients with ischemic heart disease — HR = 1.31 (95% CI: 1.19–1.45, p=0.002). All-cause mortality — HR = 1.23 (95% CI: 1.15–1.31). Both independent of LDL levels.
  • Aortic valve calcification: at Lp(a) >90 mg/dL, risk of aortic stenosis is elevated with HR = 2.90 (Patel et al., 2024) — more than threefold.
  • Independence from LDL: a large participant-level meta-analysis (Circulation, 2024) confirmed that lowering LDL with statins does not eliminate the risk attributable to Lp(a). Both factors add up.

Data on the association between Lp(a) and ischemic stroke are less consistent. Existing meta-analyses do find an association, but the strength is weaker than for myocardial infarction.

Why doesn't Lp(a) decrease with diet or exercise?

The genetic nature of Lp(a) means that standard cardiovascular risk reduction strategies work differently here. Statins — the primary tool for lowering LDL — do not reduce Lp(a), and in some patients modestly raise it. A Mediterranean diet rich in omega-3 fatty acids lowers LDL and inflammation, but has virtually no effect on Lp(a).

Niacin combined with laropiprant produced about a 30% reduction in Lp(a), but due to serious side effects the drug was withdrawn from the market in most countries. PCSK9 inhibitors (alirocumab, evolocumab) provide a modest additional effect on Lp(a) — around 20–30% alongside substantial LDL lowering.

What to do if Lp(a) is elevated?

If Lp(a) is elevated, the primary strategy is to lower all other manageable risk factors. This does not mean that high Lp(a) automatically leads to a heart attack; it means that all else being equal, the safety margin is narrower. Specific actions:

  • Find out your Lp(a) level — get a blood test (ordered separately from the standard lipid panel).
  • Discuss your personal cardiovascular risk with a cardiologist, taking Lp(a) into account.
  • Aggressively control what can be controlled: LDL, blood pressure, smoking, excess weight, physical activity.
  • Monitor clinical trial data on new drugs: pelacarsen, olpasiran, and lepodisiran reduce Lp(a) by 70–90% — phase 3 results are expected in 2026–2027.

The National Lipid Association (NLA, 2024), the European Atherosclerosis Society (EAS, 2022), and the Canadian Cardiovascular Society (CCS, 2021) recommend a one-time Lp(a) measurement for every adult — to assess lifetime risk.

What this means in practice
  • Lp(a) is a genetically determined marker. If it is elevated, changing it through diet or exercise is virtually impossible — but you can know about it and manage your other risks.
  • Getting an Lp(a) test is worthwhile at least once in a lifetime — especially if there is a family history of early heart attacks, strokes, or aortic stenosis in relatives under age 60.
  • With Lp(a) ≥50 mg/dL, LDL needs to be kept even lower than normal: each additional risk factor shifts the threshold downward.
  • Levels above 120 mg/dL warrant a cardiologist consultation and possibly early preventive measures (statins, low-dose aspirin — as indicated).
  • New targeted drugs are not yet approved, but results are expected in the next 1–2 years — this is the first real chance to lower Lp(a) specifically.

Frequently asked questions

What is Lp(a) and why should I get tested?
Lipoprotein(a) is an atherogenic particle with a unique protein, apolipoprotein(a), that inhibits fibrinolysis and accelerates atherosclerosis. It is elevated (≥50 mg/dL) in about 20% of people, is 70–90% genetically determined, and is not included in the standard lipid panel. NLA (2024), EAS (2022), and CCS (2021) recommend testing at least once in a lifetime.
What Lp(a) level is considered dangerous?
NLA (2024): intermediate risk — 30–50 mg/dL, high risk — ≥50 mg/dL (≥125 nmol/L). At levels above 120 mg/dL, Mendelian randomization indicates a 3–4 times increase in relative risk of myocardial infarction. For aortic stenosis, Lp(a) >90 mg/dL is associated with HR=2.90.
Does diet or exercise reduce Lp(a) levels?
Essentially no. Lp(a) is 70–90% genetically determined and does not respond to lifestyle changes. Statins do not lower it. PCSK9 inhibitors provide a modest effect (20–30%). The main strategy is aggressive correction of all other manageable risk factors: LDL, blood pressure, smoking, weight.
Are there new drugs specifically targeting Lp(a)?
Pelacarsen, olpasiran, and lepodisiran — RNA interference and antisense drugs — reduce Lp(a) by 70–90% in phase 2–3 trials. As of 2025, none have received regulatory approval; phase 3 data are expected in 2026–2027.

Sources

  1. Dong G, Ruan X, Gao Y, Liu Y, Ren C. «Effect of Increased Level of Lipoprotein(a) on Cardiovascular Outcomes in Patients With Ischemic Heart Disease: A Systematic Review and Meta-Analysis». Front. Cardiovasc. Med. 2024; PMC11608083. pmc.ncbi.nlm.nih.gov/articles/PMC11608083/
  2. Patel AP et al. «Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease». Frontiers in Cardiovascular Medicine. 2024; PMC11836235. pmc.ncbi.nlm.nih.gov/articles/PMC11836235/
  3. Hagström E et al. «Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis». Circulation. 2024. DOI: 10.1161/CIRCULATIONAHA.124.069556. ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069556
  4. Handelsman Y et al. «A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice». J. Clin. Lipidol. 2024. lipid.org/sites/default/files/files/PIIS1933287424000333.pdf
  5. Kronenberg F et al. «Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement». Eur. Heart J. 2022;43(39):3925–3946. DOI: 10.1093/eurheartj/ehac361. doi.org/10.1093/eurheartj/ehac361
  6. Orsó E, Schmitz G. «Lipoprotein(a) and its role in cardiovascular disease, autoimmune disease, and kidney disease: a review». PMC10959503. 2024. pmc.ncbi.nlm.nih.gov/articles/PMC10959503/
This material is for educational purposes only and does not constitute medical advice.

Know your markers. Control what can be controlled.

Anvil builds a programme around your data — training load, nutrition, and recovery in one system.

Open in Telegram